Redeye provides an update following Acarix’s Q1 2026 report, which showed revenues in line with estimates despite FX headwinds and a materially lower cost base than expected, supported by continued cost-saving initiatives. The company also delivered a record number of CADScor systems in the US during the quarter. We make slight positive revisions to our short-term cost base assumptions, but the impact on our valuation is limited. As such, we reiterate our fair value range.
LÄS MER
